Agents that indirectly target c-FLIP, such as the drug entinostat (also known as MS-275 or SNDX-275) used for aromatase inhibitor-resistant breast cancer, have a therapeutic window and usefulness which suggests more specific c-FLIP-targeted agents will also be tolerated and effective. The gene discussed is CYP19A1; the disease is breast carcinoma.